0001778922-26-000020
SEC filingSpyGlass Pharma, Inc. reported a net loss of $39.9 million for the fiscal year ended December 31, 2025, compared to a net loss of $29.2 million in the prior year. The increased loss was driven by higher operating expenses, primarily in research and development, which rose to $29.2 million from $19.9 million, and general and administrative expenses, which increased to $12.3 million from $7.1 million. The company generated no revenue, as it has no products approved for commercial sale. Cash and cash equivalents, along with short-term investments, totaled $107.4 million as of year-end. Management believes existing capital, including proceeds from its February 2026 IPO, is sufficient to fund operations through 2028 as it advances its lead product candidate, the BIM-IOL System, through Phase 3 clinical trials.
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company with no products approved for commercial sale and consequently, no revenue. The company's financial performance for the fiscal year ended December 31, 2025, reflects its ongoing investment in research and development. Total operating expenses increased to $41.4 million from $27.1 million in the prior year. This increase was driven by a $9.2 million rise in research and development expenses to $29.2 million and a $5.2 million increase in general and administrative expenses to $12.3 million. The net loss for the year was $39.9 million, compared to a net loss of $29.2 million in 2024. Other income of $1.6 million, primarily from interest income of $3.1 million, partially offset the operating loss.
The company does not generate any revenue from product sales. Its business model is entirely focused on the research and development of its product candidates, including its lead candidate, the BIM-IOL System, which is designed to treat open-angle glaucoma and ocular hypertension. The company's ability to generate future revenue is entirely dependent on the successful development, regulatory approval, and commercialization of its product candidates. No segment or geographic revenue data is disclosed, as the company operates as a single segment with no commercial operations.
As a pre-revenue company, traditional margin metrics such as gross margin and operating margin are not applicable. The company's financial results are characterized by significant operating losses driven by research and development costs. The loss from operations was $41.4 million for FY 2025. The company's cost structure is dominated by R&D activities related to clinical trials and the development of its SpyGlass Platform technology. General and administrative costs have also increased as the company builds infrastructure to support its operations as a public company and its development programs.
Net cash used in operating activities was $32.7 million for the year, an increase from $22.0 million used in the prior year, consistent with the higher net loss. Cash flows from financing activities provided $124.6 million, primarily from the issuance of redeemable convertible preferred stock ($127.3 million gross proceeds). This resulted in a net increase in cash and cash equivalents of $80.1 million. As of December 31, 2025, the company reported total assets of $115.9 million, including cash and cash equivalents of $96.4 million and short-term investments of $11.1 million. Total liabilities were $10.2 million, and total stockholders' deficit was $98.8 million, resulting in a strong liquidity position to fund future operations.
Management's discussion indicates the company expects to continue incurring significant losses for the foreseeable future as it advances its clinical programs. The lead product candidate, the BIM-IOL System, is in Phase 3 clinical trials, with enrollment expected to be completed in 2027 and a planned NDA submission to the FDA in 2028, pending successful trial results. Management believes that its existing cash, cash equivalents, and short-term investments of $107.4 million, together with the net proceeds from its February 2026 IPO, will be sufficient to fund its operating expenses and capital expenditure requirements through 2028. Key risks highlighted include dependence on the success of the BIM-IOL System, the need for substantial additional capital, intense competition, regulatory approval uncertainties, and intellectual property challenges.